Histotripsy Cancer Treatment: FDA Status and Kidney Trial News

As HistoSonics seeks FDA authorization to expand its sound-wave cancer treatment beyond the liver, patients are asking a simple question: how fast can government approve what science has already proven works?

A tumor can now be turned to liquid without a single incision.
That is not a hypothetical. It is happening right now in hospitals across 18 states, using a technology called histotripsy that destroys cancer with focused sound waves instead of a scalpel, radiation, or chemotherapy. In May 2026, the company behind the device, HistoSonics, asked the FDA to approve its use for kidney tumors, the technology’s next major test. The question is whether federal review will move as fast as the science already has.

How Does Histotripsy Actually Destroy a Tumor?
The mechanism is mechanical, not thermal. A device called the Edison System aims focused ultrasound pulses at a tumor from outside the body, generating clouds of microscopic bubbles that rapidly expand and collapse. That cavitation physically shreds the tumor’s cellular structure, turning it into a liquid the body clears on its own, without heat, cutting, or ionizing radiation. Physicians guide the process using real-time imaging, watching the tumor break down as the procedure happens.
Doctors and researchers describe it as fundamentally different from existing ablation methods like radiofrequency or microwave therapy, which rely on burning tissue and can damage nearby structures. Because histotripsy is purely mechanical, it is designed to spare healthy tissue surrounding the target. Many patients go home the same day.

What Has Histotripsy Already Proven in Liver Cancer?
This is not an unproven idea. The FDA granted the Edison System De Novo marketing authorization in October 2023, based on the #HOPE4LIVER trial, which enrolled 44 patients at 13 sites across the U.S. and Europe [company/FDA data]. The trial reported a 95.5 percent technical success rate destroying targeted liver tissue, with three serious adverse events across all 44 patients treated.
Since then, adoption has scaled fast. More than 2,000 patients have been treated at over 50 U.S. medical centers, and Edison systems now operate in 18 states plus the United Arab Emirates and Hong Kong [HistoSonics company data]. A one-year follow-up study published in the Annals of Surgery tracked those early liver patients and continued to report favorable safety outcomes, the kind of longer-term data regulators and physicians look for before trusting a new mechanism [peer-reviewed clinical data]. That track record is why the technology’s next move, into kidney cancer, matters so much to patients watching the calendar.

Why Is Kidney Cancer the Next Battleground?
680,000 people are currently living with kidney tumors in the United States. The question patients are asking: how long will they wait for an option that already works on a different organ?
HistoSonics submitted its kidney tumor application to the FDA in May 2026, backed by the #HOPE4KIDNEY pivotal trial, which finished enrolling 67 patients in June 2025 [company trial data]. Current standard treatments for kidney tumors, partial nephrectomy or thermal ablation, are invasive and carry risks of bleeding, infection, and lost kidney function. Roughly 80,000 new kidney cancer cases will be diagnosed in the United States this year alone [American Cancer Society estimate]. A treatment that already works without surgery on one organ is now waiting on a government agency to say yes for another.

Who Is Really Driving This Innovation?
Histotripsy did not come from a federal program. It came from a University of Michigan lab, where biomedical engineering professor Charles Cain coined the term in 2003 and mentored a graduate student named Zhen Xu, who carried the research through two decades of development. Cain died in 2020, three years before his invention received its first FDA clearance. Xu, now a Li Ka-Shing Endowed Professor at Michigan, was named to Time’s 2026 list of the 100 most influential health leaders for the work.
The company they co-founded in 2009, HistoSonics, was acquired last August for 2.25 billion dollars by a consortium of private investors, capital now funding expansion into kidney, pancreatic, and prostate applications [company acquisition data]. It is a case study in what American research universities and private capital can build when left to compete: two decades of unglamorous engineering work turning into a treatment already reaching thousands of patients. No federal mandate ordered histotripsy into existence. A university lab, a small startup, and investors willing to bet on a two-decade research timeline did that on their own, long before any government agency signed off.

What Do Skeptics of Fast-Tracking New Medical Devices Actually Believe?
Caution here is not unreasonable. Critics of accelerated device pathways argue that new indications, like kidney and pancreatic tumors, involve different tissue, different risks, and thinner evidence than the original liver approval. They point to past medical devices that reached market quickly and were later linked to complications regulators missed the first time. That is a fair concern, and it deserves a real answer rather than dismissal.

Is a treatment only worth trusting once the paperwork catches up to the biology?

The answer is that histotripsy’s kidney application is not skipping scrutiny. It is going through the same De Novo pathway, backed by a dedicated multi-site pivotal trial, that the liver indication already completed successfully. Rigorous review and a faster timeline are not mutually exclusive, and the FDA’s own Breakthrough Devices Program exists specifically to prioritize technologies like this one without lowering the evidence bar.

What Happens If Review Timelines Don’t Keep Pace With the Science?
The FDA’s original liver review, from De Novo submission to clearance, took roughly two years. If kidney cancer patients wait that same two years for a decision, how many of them will still have had the choice to use it? Every month a promising, already-proven mechanism sits in review is a month patients spend choosing between older, more invasive options or waiting on a federal timeline they do not control.
This is not a call to abandon safety review. It is a question about whether an agency that already validated this exact mechanism for one organ should move with more urgency validating it for another, especially when the underlying trial data continues to be described by investigators as showing “promising insights” into safety and effectiveness.

Key Questions This Story Raises

• How long should regulatory review take once a core technology is already FDA-validated for one indication?
• Who bears the cost, financial and physical, of a slower approval timeline: the agency, the company, or the patient?
• Should federal reviewers weigh the burden of delay on patients as heavily as they weigh the risk of moving too fast?

Is This the Accountability Moment Patients Have Been Waiting For?
Innovation is not the bottleneck anymore. A private university lab and private capital already solved the hard scientific problem, twice. What remains is a bureaucratic one: whether the system built to protect patients can also move fast enough to serve them. That is not a knock on any single official. It is a structural question about how government agencies weigh patient urgency against institutional caution.
The real question is not whether histotripsy works. That has already been answered, one liquefied tumor at a time. The question is whether the next patient waiting on a kidney diagnosis will get the same chance, on the same government’s timeline, or whether they will run out of time first.

What do you think? Should federal review move faster once a core technology is already proven, or is caution always worth the wait? Share this story and tell us where you land.
Still have questions about how this technology reaches patients near you? Subscribe for ongoing coverage as the kidney tumor decision develops. Want your voice to count? Contact your representative on the House Energy and Commerce Committee, which oversees FDA device policy, and ask directly about the pace of the Breakthrough Devices Program.